Gamida Cell Ltd.

GMDA

IL0011552663

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:54:51 2024-05-24 EDT			5-day change	1st Jan Change
0.017 ^USD	+2.41%		-.--%	-95.88%

06-18	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
06-18	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI

Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC

June 17, 2024

On June 18, 2024, Gamida Cell Ltd. closed the transaction.

Latest news about Gamida Cell Ltd.

Gamida Cell Names Rory Nealon as Chief Financial Officer	06-18	CI
Gamida Cell Names Sheila Frame as Chief Commercial Officer	06-18	CI
Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	06-18	CI
Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	06-17	CI
Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	04-09	CI
Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	04-04	CI
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	03-28	MT
Top Premarket Decliners	03-28	MT
Top Midday Decliners	03-27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	03-27	MT
Transcript : Gamida Cell Ltd., Q4 2023 Earnings Call, Mar 27, 2024	03-27
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	03-27	MT
Top Premarket Decliners	03-27	MT
Gamida Cell Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Gamida Cell Ltd. Announces Cessation of Executives	03-27	CI
Gamida Cell Ltd. announced that it expects to receive $30 million in funding from Highbridge Capital Management, LLC	03-26	CI
JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	01-29	MT
Gamida Cell Exploring Strategic Alternatives; Shares Rise	01-29	MT
Gamida Cell Actively Pursuing Strategic Alternatives	01-28	CI
Transcript : Gamida Cell Ltd. - Special Call	12-04
Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	11-15	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	11-15	MT
Gamida Cell Ltd. Announces Resignation of Mr. Jeremy Blank as Board of Director	11-15	CI
Transcript : Gamida Cell Ltd., Q3 2023 Earnings Call, Nov 14, 2023	11-14

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GAMIDA CELL LTD.	-95.88%	2.62M
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.73%	115B
ARGENX SE	+22.18%	26.64B
BIONTECH SE	-21.81%	19.91B
GENMAB A/S	-16.89%	16.32B
BEIGENE, LTD.	-18.81%	15.49B
WUXI APPTEC CO., LTD.	-44.74%	15.52B
SAREPTA THERAPEUTICS, INC.	+62.72%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.67B